Together, our findings highlight that hybrid compounds similar to 6b that are novel, direct STAT3 inhibitors with ROS production activity are worth further investigation as potential therapeutics for breast cancer or drug-resistant breast cancer. This evidence concerns the gene STAT3 and breast cancer.